OmniRayn
← All repurposing reports
S2 (505(b)(2))

epilepsy syndrome

Known, approved drugs ranked as repurposing candidates for epilepsy syndrome — each scored for reversal of the disease expression signature, cytotoxicity-filtered, and prioritized by clinical maturity. Computational, pending wet-lab.

Preview. Candidate identities are shown below. The full ranking, quantified reversal scores, per-candidate mechanistic rationale, ClinicalTrials.gov whitespace detail, and structure-function intelligence are included with the dossier.

Top candidates preview

  1. 1sulindacApproved
  2. 2pentoxifyllineApproved
  3. 3cisaprideApproved
  4. 4oxaprozinApproved
  5. 5ranolazineApproved
  6. 6indometacinApproved
  7. 7dasatinibApproved
  8. 8lovastatinApproved

Full dossier — 150 cytotox-screened candidates

Quantified reversal ranking · mechanistic rationale · CT.gov whitespace · S2 (505(b)(2)) regulatory framing · structure-function intelligence.

Acquire dossier — $3,950